Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

191.16 -1.41 (-0.73%)
Delayed Quote Updated: 2:20 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy? ↗
Moderna's stock recently hit a new 52-week high after receiving positive news surrounding one of its vaccines. 
Via The Motley Fool
News headline image
Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence
News headline image
Moderna: A Stock to Watch or a Risky Bet? ↗
Could Moderna be the next big opportunity in biotech? Join our experts as they dissect the company's strengths and weaknesses, revealing insights that could shape your investment strategy. 
Via The Motley Fool
News headline image
Therapeutics Stocks Q1 Highlights: Moderna (NASDAQ:MRNA)
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Moderna (NASDAQ:MRNA) and its... 
Via StockStory
Topics Artificial Intelligence
These S&P500 stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
News headline image
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
Looking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers. Over the ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Should You Buy Moderna Stock Hand Over Fist Before Aug. 5? ↗
The biotech has been on a tear lately. 
Via The Motley Fool
News headline image
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback? ↗
A fresh era of earnings growth may be on the horizon. 
Via The Motley Fool
News headline image
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?
The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly th... 
Via StockStory
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Natera (NASDAQ:NTRA) and its ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
Via StockStory
Topics Artificial Intelligence
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Which S&P500 stocks are gapping on Friday? ↗
Via Chartmill
News headline image
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? ↗
Additional blockbuster drugs may be on the horizon. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Moderna (MRNA) Stock Is Trading Up Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 2.6% in the afternoon session after the European Commission signed a contract to ... 
Via StockStory
News headline image
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
From Moderna, Inc.
Via ACCESS Newswire
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
Gapping S&P500 stocks in Wednesday's session ↗
Via Chartmill
Wednesday's pre-market session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Moderna Appoints Michael McDonnell to Board of Directors
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Stock Is Soaring. Is It Too Late to Buy? ↗
Moderna's growth story is just beginning. 
Via The Motley Fool
News headline image
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗
These stocks have jumped in the double- and triple-digits. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
Stay informed with the top movers within the S&P500 index on Monday. ↗
Via Chartmill
Monday's pre-market session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Wall Street Got the Weak Jobs Report It Wanted. Chip Stocks Wrecked the Rally Anyway. ↗
Via Chartmill
News headline image
MarketBeat Week in Review – 06/29 - 07/03 ↗
MarketBeat's weekly roundup covers a weaker June jobs report, tech sector rotation, and top analyst picks including TSLA, AVGO, PLTR, MRNA, and NEE heading into Q2 earnings season. 
Via MarketBeat
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.